Clinical trial · Observational
Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)
Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)
NCT03099031CI-TRIAL-00042305PREDICAREcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to validate the Ottawa score (risk of thromboembolic recurrences) in cancer patients with thromboembolic disease treated with tinzaparin (Innohep®)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Venous Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tinzaparin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Tinzaparin
- description
- Patients with objectively confirmed cancer associated venous thromboembolism receiving tinzaparin treatment to prevent recurrence of venous thromboembolism
- interventionNames
- Drug: Tinzaparin
Primary outcomes (1)
- measure
- Venous thromboembolism recurrence
- timeFrame
- 6 months
Secondary outcomes (3)
- measure
- Major hemorrhage
- timeFrame
- 6 months
- measure
- Death
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer patients with histologically confirmed, active or evolving, solid or liquid tumour, or * Suspected malignant tumour confirmed within a month of index VTE occurrence * Treated with specific metastatic or adjuvant anti-cancer treatment * Patients with recent diagnosis of documented symptomatic or incidental VTE and a prescription of tinzaparin for 6 months * Proximal or distal VTE of lower limbs * Pulmonary embolism * Inferior or superior vena cava thrombosis * Iliac vein thrombosis Exclusion Criteria: * Skin cancer other than melanoma * Life expectancy less than 6 months * Superficial isolated thrombosis * Isolated subsegmental pulmonary embolism * Cerebral, visceral thrombosis * Superior limbs VTE or Central catheter thrombosis * Patients being treated with anticoagulants by more than 7 days
References
Publications (0)
Data not yet available
No reference posted for this study.